# US 10,500,202 B2 · Pharmaceutical formulation containing tadalafil

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,500,202 B2
- Document ID: US10500202B2
- Status: Granted
- Kind: B2
- Application number: 15/827,417
- Filed: 2017-11-30
- Published: 2018-06-14
- Granted: 2019-12-10
- Earliest claimed: 2016-11-30
- Assignees: Druggability Technologies IP Holdco Limited
- Applicants: Druggability Technologies IP Holdco Limited
- Inventors: Betti Szabóné Ordasi; Tamás Jordán; Richárd Balázs Kárpáti; Andrea Ujhelyi; Tamás Solymosi; Hristos Glavinas; Genovéva Filipcsei
- Web page: https://patentgrep.com/patent/US10500202B2

## CPC

- A61K 31/4985: Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A61K 9/1617: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/1635: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/1682: {Processes}
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K 47/20: containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
- A61K 47/32: Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers {, poly(meth)acrylates, or polyvinyl pyrrolidone}
- A61P 9/12: Antihypertensives
- A61P 13/08: of the prostate
- A61P 15/10: for impotence
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed herein are pharmaceutical compositions comprising Tadalafil, or a salt, or derivatives thereof and pharmaceutical excipients, processes for the preparation thereof, and pharmaceutical compositions containing them. The pharmaceutical compositions have improved physicochemical properties that provide faster onset of action for the treatment of erectile dysfunction.

## Claims

### Claim 1

A pharmaceutical composition comprising
10-40% by weight of Tadalafil or a salt thereof;
35-70% by weight of a primary pharmaceutical excipient which is copovidone (copolymer of vinylpyrrolidone and vinyl acetate); and
5-50% by weight of a secondary pharmaceutical excipient which is sodium lauryl sulfate;
wherein said pharmaceutical composition is obtained by a process comprising mixing followed by spray-drying;
wherein said pharmaceutical composition has a controlled particle size in the range between 10 nm and 500 nm; and
wherein said pharmaceutical composition shows X-ray amorphous character in the solid form.

### Claim 2 (depends on 1)

The pharmaceutical composition as recited in claim 1, wherein said composition is characterized by said Raman spectrum as shown in FIG. 7.

### Claim 3 (depends on 1)

The pharmaceutical composition as recited in claim 1, wherein said particle size is between 10 nm and 200 nm.

### Claim 4 (depends on 1)

The pharmaceutical composition as recited in claim 1, wherein said pharmaceutical composition shows a tmax of 0.5-0.75 hours.

### Claim 5 (depends on 1)

The pharmaceutical composition as recited in claim 1, wherein said pharmaceutical composition has a dissolution profile such that about 60% of the pharmaceutical composition is dissolved in simulated gastric fluid over two hours.

### Claim 6 (depends on 1)

A pharmaceutical dosage form comprising the pharmaceutical composition according to claim 1, together with pharmaceutically acceptable excipients.

### Claim 7 (depends on 6)

The pharmaceutical dosage form comprising the pharmaceutical composition according to claim 6, wherein said pharmaceutical dosage form is suitable for oral administration.

### Claim 8 (depends on 1)

The pharmaceutical composition as recited in claim 1, wherein the pharmaceutical composition has an apparent solubility in water of at least 0.7 mg/mL.

### Claim 9 (depends on 1)

The pharmaceutical composition as recited in claim 1, wherein the pharmaceutical composition has a PAMPA permeability of at least 4×10−6 cm/s when dispersed in water, FaSSIF or FeSSIF biorelevant media, which does not decrease in time at least for 6 months.